Brief: Actinium Further Strengthens Patent Portfolio With International Ip Covering The Composition And Methods Of Administration Of Iomab-B Antibody Radiation Conjugate In The EU And Japan
17/06/2021 13:38
June 17 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM FURTHER STRENGTHENS PATENT PORTFOLIO WITH
INTERNATIONAL
IP COVERING THE COMPOSITION AND METHODS OF ADMINISTRATION OF
IOMAB-B ANTIBODY RADIATION CONJUGATE IN THE EU AND JAPAN
* ACTINIUM PHARMACEUTICALS INC - ISSUED PATENT IN EU AND
GRANTED
PATENT IN JAPAN EXPECTED TO HAVE A USEFUL LIFE THROUGH 2036
Source text for Eikon: ID:nPn9m2hzNa
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities